Abstract
The objective of the study was to evaluate the ability of meropenem to reach the bronchial lumen. 24 patients undergoing fibreoptic bronchoscopy for exploratory purposes were given a single dose of meropenem 1 g as an (i.v.), infusion over 30 min. Plasma (P) sampling times were: 0, 0.5, 1, 2 and 3 h. Bronchial secretions (BS) were collected by fibreoptic bronchoscopy at the same sampling times (except for 0 and 0.5 h) in three groups of 8 patients. Meropenem was measured by bioassay using E. coli ATCC 39118 as the test-organism.
The results showed that meropenem had reached a high plasma concentration at the first sampling time (59.8 mg · 1−1) and then the plasma level decreased rapidly to 10.6 mg · 1−1 and 2.7 mg · 1−1 at 2 and 3 h respectively. The highest concentration achieved in bronchial secretion was 0.53 mg · 1−1 in the third hour, ie 20% of the serum level.
The data indicate significant penetration of meropenem into bronchial secretions and achievement of a local level sufficiently high to eradicate most respiratory pathogens.
References
Barza M (1981) Principles of tissue penetration of antibiotics. J Antimicrob Chemother 8 [Suppl C]: 7–28
Bergogne-Bérézin E (1993) Pharmacokinetics of antibiotics in respiratory tissues and fluids. In Pennington JE (ed) Respiratory infections: diagnosis and management, 3d edn. Raven Press, New York (in press)
Honeybourne D, Baldwin DR (1992). The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother. 30: 249–260
Pennington JE (1981) Penetration of antibiotics into respiratory secretions. Rev Infect Dis 3: 67–73
Valcke Y, Pauwels R, Van der Streten M (1990) Pharmacokinetics of antibiotics in the lungs. Eur Respir J 3: 715–722
May JR, Delves DM (1965) Treatment of chronic bronchitis with ampicillin: some pharmacological observations. Lancet I: 929–933
Stewart SM, Anderson IME, Jones GR, Galder MA (1974) Amoxycillin levels in sputum, serum and saliva. Thorax 29: 110–114
Bergogne-Bérézin E, Muller-Serieys C, Kafé H (1992) Penetration of lomefloxacin into bronchial secretions following single and multiple oral administration. Am J Med 92 [Suppl 4A]: 4A-8S
Ravizzola G, Pinsi G, Gonzales R, Colombrita D, Pirali F, Turano A (1989) Antibacterial activity of the new carbapenem meropenem (SM-7338) against clinical isolates. Eur J Clin Microbiol Infect Dis 8: 1053–1064
Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S (1993) Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 37: 229–233
Nilsson-Ehjle I, Hutchison M, Haworth SJ, Norrby SR (1991) Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 10: 85–88
Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ (1989) The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 24 [Suppl A]: 311–320
Harrison MP, Moss R, Featherstone A, Fowkes AG, Sanders AM, Case DE (1989) The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 24 [Suppl A]: 265–277
Wise R, Logan M, Cooper M, Ashby JP, Andrews JM (1990) Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother 34: 1515–1517
Muller-Serieys C, Bergogne-Bérézin E, Rowan C, Dombret MC (1987) Imipenem penetration into bronchial secretions. J Antimicrob Chemother 20: 618–619
Jones RN, Barry AL, Thornsberry C (1989) In vitro studies of meropenem. J Antimicrob Chemother 24 [Suppl A]: 9–29
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bergogne-Bérézin, E., Muller-Serieys, C., Aubier, M. et al. Concentration of meropenem in serum and in bronchial secretions in patients undergoing fibreoptic bronchoscopy. Eur J Clin Pharmacol 46, 87–88 (1994). https://doi.org/10.1007/BF00195922
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00195922